Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)
Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system, without causing inflammation.